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Summary In the last decades there has been an increase in cases of visceral leishmaniasis
complicating the post-transplant phase, mainly following kidney transplantation. The aim of
this study was to evaluate the reactivity of haemodialysed patients using IFAT. Blood samples
of 310 individuals from Natal, RN, Brazil, were collected and analysed. Data regarding bloodLeishmania chagasi;
Haemodialysis;
Kidney transplant;
Asymptomatic
infection;
transfusion, cause of end-stage renal disease and duration of haemodialysis were also analysed.
In total, 69 patients (22.3%) were positive by IFAT. This study suggests that antibody detection
should be performed in this group of patients since they are possible candidates for kidney
transplantation.
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1. IntroductionA great number of visceral leishmaniasis (VL) cases occur in
immunocompromised hosts due to various causes, including
renal transplantation, AIDS, haematological malignancies
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nd corticosteroid therapy.1 In this investigation, antibody
revalence in haemodialysed individuals was studied by
FAT, as patients undergoing haemodialysis are possible renal
ransplant candidates.
. Patients and methods.1. Population studied
rom December 2006 to March 2007, data and sera from
10 individuals were collected. The population comprised
ndividuals diagnosed with end-stage renal disease (ESRD)
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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Table 1 Reactivity in IFAT by gender, blood transfusion, cause of end-stage renal disease (ESRD) and duration of haemodialysis
IFAT-positive [n (%)] IFAT-negative [n (%)] P-value
Gender
Male 37 (22.6) 127 (77.4) 0.892
Female 32 (21.9) 114 (78.1)
Blood transfusion
Yes 17 (21.0) 64 (79.0) 0.749
No 52 (22.7) 177 (77.3)
Cause of ESRD
Diabetes 16 (24.2) 50 (75.8) 0.443
HN 28 (24.6) 86 (75.4)
CG 10 (14.7) 58 (85.3)
TIN 6 (31.6) 13 (68.4)
Miscellaneous 9 (20.9) 34 (79.1)
Duration of haemodialysis
<1 year 14 (23.3) 46 (76.7) 0.118
1—5 years 25 (17.4) 119 (82.6)
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n>5 years 30 (28.3)
HN: hypertensive nephrosclerosis; CG: chronic glomerulonephritis
ndergoing haemodialysis in the Nefron Clínica, located in
atal, Rio Grande do Norte, northeastern Brazil, an area
ndemic for VL. The participants were all residents in this
tate. Individuals with a past history of malaria, cutaneous
eishmaniasis, Chagas disease or VL were excluded from the
tudy. All participants gave informed consent before enter-
ng the study.
.2. Serological method
FAT was the laboratory test available and was performed
ith a commercial kit (FIOCRUZ/Bio-Manguinhos, Rio de
aneiro, Brazil) using promastigotes as antigens. Titres equal
o 1:40 were considered positive. All samples were also
ested by ELISA for Chagas disease owing to the possibility
f cross-reaction.
.3. Statistical analysis
he independent variables analysed were age, gender, blood
ransfusion, duration of haemodialysis and cause of ESRD.
The Mann-Whitney U-test was used to assess differences
etween the variables age and anti-Leishmania serological
esults. The 2 test was used to assess the association of
ategorical variables with the positive anti-Leishmania sero-
ogical status. Results were considered to be statistically
igniﬁcant at P < 0.05. All analyses were done using SPSS
oftware (SPSS Inc., Chicago, IL, USA).. Results
rom the 310 individuals tested, 69 (22.3%) were IFAT-
ositive. Only 1 (0.3%) was positive by ELISA for Chagas
isease, however he was not positive by IFAT. No association
as observed. These results are shown in Table 1.
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: tubulointerstitial nephritis.
. Discussion
n adulthood, VL is more prevalent in men and this pat-
ern was conﬁrmed in this study, although the difference
as small (1.1:1.0) and was not statistically signiﬁcant.
owever, the physician should be aware that in the post-
ransplant phase the male population is more affected by
L.1
In the present study, blood transfusion was not shown to
e associated with reactivity in IFAT, although Luz et al.2
emonstrated a reactivity of 37% to VL in haemodialysed
olytransfused patients from the same region during a bur-
en of VL. The presence of antibodies against Leishmania
nd its DNA in blood donors has also been found,2 indi-
ating that these individuals are asymptomatic reservoirs.
hus, blood transfusion might be a risk factor for VL and
ossibly inﬂuences reactivity in IFAT or another serological
est. A possible explanation for the non-association may be
he use of erythropoietin to treat the anaemia of ESRD in
aemodialysed patients, markedly decreasing the number
f blood transfusions in this population.3
Although VL is known to cause interstitial nephritis,
lomerulonephritis or both, in general acute and mild,4 we
ypothesised that there could be a chronic immune complex
eposition in reactive patients, provoking ESRD, however
he cause of ESRD was not associated with reactivity in IFAT.
We also hypothesised that the prevalence of reactiv-
ty might be underestimated due to the state of chronic
raemia, which causes dysfunction of the immune system.5
here is greater susceptibility to infections, hyporesponsive-
ess to vaccination and impairment of cellular and humoral
mmunities.5Although IFAT does not discriminate between past and
urrent infections and presents cross-reactions with others
iseases, such as malaria, cutaneous leishmaniasis and Cha-
as disease, these inﬂuences could be attenuated because
one of the subjects had a past history of them, the ﬁrst two
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diseases are not present in the study region and the ELISA
for Chagas disease was reactive in only one patient.
In conclusion, this study reveals a high prevalence of pos-
itive serology in haemodialysed individuals, meaning that
they were already infected by Leishmania, thus in the future
it may become a problem during an immunosuppressive
state. The authors recommend that routine serology for VL
in haemodialysed patients should be performed, at least in
endemic areas, because VL presents a high mortality rate
in the post-transplant phase owing to immunosuppression,1
and reactive serology might lead to a prompt diagnosis. We
also have the same opinion as other authors, thus we rec-
ommend the investigation of VL in individuals who live in an
endemic area or have previously visited them and present
with persistent fever during the haemodialysis course or
post-transplant phase.
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